About Orakl Oncology
Orakl Oncology develops large cohorts of patient-derived organoids (PDO), from which we generate large volumes of data and train proprietary AI algorithms to help pharma teams develop new treatments for patients. In practice: we culture ~100 PDOs in parallel at any given time in the lab, screen dozens of drugs weekly and own a growing biobank with and an expanding client portfolio.